8-K: Kyverna Therapeutics Presents Positive Data Update on KYV-101 CAR T-Cell Therapy at EULAR Symposium

Kyverna Therapeutics shared an update on its KYV-101 CAR T-cell therapy, highlighting promising safety and efficacy data across multiple autoimmune diseases at an industry symposium.

Summary

• Kyverna Therapeutics presented an update on its KYV-101 CAR T-cell therapy at the EULAR symposium in Vienna on June 14, 2024.
• The presentation included data from 50 patients treated with the KYV-101 CAR construct, with 30 of those patients having autoimmune diseases.
• The KYV-101 construct is a fully human anti-CD19 CAR T-cell therapy designed for improved safety, based on research from the NIH.
• Early data shows promising outcomes across multiple indications including rheumatology, hematology and neurology.
• The therapy has demonstrated CAR T-cell expansion, B-cell depletion, and autoantibody reduction, leading to disease impact and durable immunomodulator-free response (DIFR).
• In a study of 20 patients with B-cell lymphoma, the KYV-101 construct showed reduced neurologic toxicity and cytokine production compared to the YESCARTA construct.
• In 30 patients with autoimmune diseases, no Grade 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.
• The company is pursuing a three-pillar strategy including named patient use, company-sponsored clinical trials, and investigator-initiated clinical trials.
• The pipeline includes KYV-101 for rheumatology (lupus nephritis, systemic sclerosis) and neurology (myasthenia gravis, multiple sclerosis), as well as KYV-201 for multiple indications using CRISPR/Cas9 technology.
• Early data from lupus nephritis patients shows a reduction in anti-dsDNA antibodies and normalization of complement components, with some patients achieving disease control without immunosuppressants.

Sentiment

Score: 8

Explanation: The document presents very positive early data for KYV-101, with a focus on safety and efficacy. The company is clearly making progress in a promising area of medicine. However, it is still early stage and there are risks associated with clinical trials and the long term efficacy of the treatment.

Positives

• The KYV-101 CAR T-cell therapy shows a promising safety profile with no Grade 3 CRS or ICANS observed in 30 autoimmune patients.
• The therapy demonstrates effective B-cell depletion and reduction in autoantibodies.
• Early data suggests a durable immunomodulator-free response (DIFR) is achievable, with the first patient treated being disease-free after one year.
• The fully human design of the KYV-101 construct may contribute to its improved safety profile.
• The company is pursuing a multi-faceted clinical trial strategy to gather data and expand the use of KYV-101.

Negatives

• Some patients experienced a recurrence of disease after an initial response, particularly at lower cell doses.
• There is high variability in short-term results, particularly in proteinuria levels in lupus nephritis patients.
• The data presented is primarily from early-stage trials and case reports, not large-scale clinical trials.
• The long-term efficacy and safety of KYV-101 are still being evaluated.

Risks

• The clinical trial results may not confirm the safety and efficacy observations discussed in case reports and studies.
• CAR T-cell therapies are associated with class effects, including CRS and ICANS, which may be potentially serious or life-threatening.
• The company's success depends on the successful development and regulatory approval of its drug candidates.
• There is a risk of disease recurrence after initial treatment response.
• The company is reliant on third parties for manufacturing and supply of its therapies.

Future Outlook

Kyverna plans to advance a broad clinical trial program across a range of rheumatic and neurologic autoimmune diseases, leveraging the promising early data from KYV-101.

Management Comments

• Peter Maag, PhD, Chief Executive Officer of Kyverna Therapeutics, welcomed attendees and introduced the symposium.
• James Chung, MD, PhD, Chief Medical Officer, presented the KYV-101 experience across multiple diseases and sites.

Industry Context

The presentation highlights the growing interest in CAR T-cell therapy for autoimmune diseases, a field that is shifting from traditional small molecules and biologics to cell-based therapies. Kyverna is positioning itself as a leader in this emerging space, focusing on a fully human construct for improved safety.

Comparison to Industry Standards

• The KYV-101 construct is designed to improve upon existing CAR T-cell therapies like axicabtagene ciloleucel (YESCARTA) by using a fully human single-chain variable fragment and human CD8 hinge and TM domains.
• The data presented suggests reduced neurologic toxicity and cytokine production compared to YESCARTA, which is a significant advantage.
• The company is comparing its results to published data from other CAR T-cell therapies such as BREYANZI (lisocabtagene maraleucel) and KYMRIAH (tisagenlecleucel), highlighting the improved safety profile of KYV-101.
• The company is also comparing its results to published case reports of other anti-CD19 CAR T therapies in autoimmune diseases, noting the potential for a treatment-free setting with KYV-101.

Stakeholder Impact

• Shareholders may view the positive data as a positive sign for the company's future prospects.
• Patients with autoimmune diseases may see KYV-101 as a promising new treatment option.
• Employees may be motivated by the positive results and the potential to make a difference in patients' lives.
• The company's success could lead to increased demand for its therapies and potential partnerships with other companies.

Next Steps

• Kyverna will continue to enroll patients in its Phase 1/2 clinical trials for rheumatology and neurology indications.
• The company will continue to pursue investigator-initiated clinical trials to expand the understanding of KYV-101.
• Kyverna will continue to develop its pipeline of CAR T-cell therapies, including KYV-201 using CRISPR/Cas9 technology.

Key Dates

Keywords

CAR T-cell therapy, KYV-101, autoimmune diseases, lupus nephritis, myasthenia gravis, multiple sclerosis, rheumatology, neurology, B-cell depletion, immunomodulator-free response, clinical trials, cytokine release syndrome, neurotoxicity